Compare Repligen Corporation Common Stock (RGEN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Raymond James Financial, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B). The key difference: Raymond James Financial, Inc. is far larger — about 2.7× Repligen Corporation Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Raymond James Financial, Inc. for 75 Days on average.
| RGEN | RJF | |
|---|---|---|
Market Cap | $11.14B | $30.15B |
Volume | 1,259,263 | 980,106 |
Sector | Health | Financials |
52-Week High | $194.57 | $181.18 |
52-Week Low | $102.87 | $140.89 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $11.02B | $24.02B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Raymond James Financial (RJF) trades at $157.25, down 0.88% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent earnings beats, revenue growth from $10.9B in 2022 to $13.84B in 2025, and robust profitability margins. Recent news highlights executive leadership changes and a declared $0.54 dividend payable in October 2026.
The stock presents a mixed outlook: attractive valuation multiples and analyst consensus price target of $178.50 suggest upside potential, but bearish technical indicators and rising expenses pose near-term risks. Investment appeal hinges on sustained earnings growth and management's execution amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
